Risk assets declined across the globe, with European, Asian shares and S&P 500 futures all falling, while the dollar slumped against most currencies after a news conference by President-elect Donald Trump disappointed investors with limited details of his economic-stimulus plans, and the Trumpflation/reflation trade was said to be unwinding.
Another day, another market-moving tweet from Donald Trump.
Moments ago, the president-elect, following up on his recent spat with Lockheed over the F-35, which one week ago Trump said its "program and cost is out of control”, continued his crusade on over-budget government programs, when he tweeted that "based on the tremendous cost and cost overruns of the Lockheed Martin F-35, I have asked Boeing to price-out a comparable F-18 Super Hornet!"
President-elect Donald Trump, whose victory last month was greeted with a surge in pharmaceutical stocks, declared himself an opponent of high drug prices in an interview with Time magazine.
“I’m going to bring down drug prices. I don’t like what’s happened with drug prices,” Trump said, according to a transcript of the interview posted on Time’s website.
Joe Raedle/Getty ImagesWe see Republican presidential nominee Donald Trump’s unexpected victory bringing market and policy uncertainty in the short run, as we write in our new BlackRock Bulletin on the U.S. election outcome.
AFPParis (AFP) - Donald Trump's election looms large over the race for president of America's oldest ally France, where mainstream candidates all style themselves as uniquely qualified to prevent a similar upset by the far right.
This post How Biotech Stocks Trumped the Hillary Clinton Curse appeared first on Daily Reckoning.
The election may be all but over. But that isn’t stopping our fearless overlords from taking more pot-shots at biotech stocks…
Pharma CEOs breathed a collective sigh of relief after the final presidential debate ended late Wednesday evening without a single mention of rising drug prices.
President-elect Donald Trump dominated the conversation as pundits and experts debated what the future holds at the National Post’s 40th annual Outlook Luncheon. Here are their predictions for the coming year.
Trump can only do so much
Andrew Coyne, Postmedia columnist
Ty Wright/Getty ImagesDrug companies expecting less pressure on price increases under a Donald Trump administration might need to rethink their strategy.
In an interview with Time magazine the president elect offered his thoughts on the drug prices.
"I’m going to bring down drug prices. I don’t like what’s happened with drug prices."
Spencer Platt/Getty ImagesMasayoshi Son, the CEO of the Japanese telecom SoftBank, announced Tuesday that his company will invest $50 billion and bring 50,000 jobs to the US after he met with President-elect Donald Trump.